两种方案治疗慢性乙型肝炎疗效对比及成本-效果分析  

Contrast of Therapeutic Effects Between Two Schemes in Treating the CHB and the Cost-Effectiveness Analysis

作　　者：吴英梅 雷卫平 符惠燕[2] 

机构地区：[1]粤北第二人民医院,广东韶关512026 [2]广州中医药大学

出　　处：《药物流行病学杂志》2008年第1期54-56,共3页Chinese Journal of Pharmacoepidemiology

基　　金：韶关市医药卫生科研资助项目(Y04067)

摘　　要：目的:寻找一种经济、有效、安全的治疗慢性乙型肝炎(CHB)方案。方法:将符合慢性乙型肝炎标准80例分成两组。分别以A方案(n=40):注射用母牛分枝杆菌菌苗(微卡)+乙肝疫苗+潘生丁;B方案(n=40):注射用重组人干扰素α_(1b)(赛诺金)治疗。6个月为1个疗程。观察乙肝病毒的核糖核酸(HBV-DNA)、乙型肝炎e抗原(HBeAg)临床转阴率并做成本-效果分析。结果:两组有效率分别为87.5%和92.5%,两组比较差异无统计学意义(P>0.05);两组成本分别为3270.84元;10873.20元.A、B方案成本-效果比分别为37.38,117.55。结论:A方案为最佳治疗CHB经济、有效、安全的方案。Objective： To seek an economical effective and safe scheme for the treatment of CHB（ chronic hepatitis B）, Method： 80 cases of CHB were divided into two groups： Group A （n =40） ： treated with mycobacterium vaccine for injection（VACCAE） , HBB and dipyridamole In Groups B （n = 40） the medicine was recombinant human interferon α1b for injection（ SINOGEN）with one course of 6 months. The HBV-DNA, HBeAg and their clinical improvement rates were observed and the cost-effectiveness was analyzed, Result： The effective rates of 2 groups were 87.5% and 92, 5% respectively, No statistical difference（ P 〉 0. 05 ）was found in the 2 groups, The costs of the 2 groups were 3270、 84 yuan and 10 873, 20 yuan respectively, and the cost-effectiveness rates were 37, 38 and 117, 55 respectively. Conclusion： Scheme A is an effective, safe and economical scheme in the treatment of CHB.

关 键 词：母牛分枝杆菌菌苗 重组人干扰素 慢性乙型肝炎 乙肝病毒核糖核酸 乙型肝炎E抗原 成本-效果分析 

分 类 号：F407.7[经济管理—产业经济]